Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies

Acta Neuropathologica

Volumn 131, Issue 1, 2016, Pages 5-25

  Eisele, Yvonne S ^a   Duyckaerts, Charles ^b,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Institut du Cerveau et de la Moelle   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; PRION PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; BASEMENT MEMBRANE; BRAIN FORNIX; DENTATE GYRUS; DIFFUSION; ENTORHINAL CORTEX; EXTRACELLULAR SPACE; HUMAN; MAMMILLARY BODY; NEOCORTEX; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PUTAMEN; REVIEW; SENILE PLAQUE; SUBICULUM; TAUOPATHY; ANIMAL; BRAIN; DISEASE MODEL; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; TAU PROTEINS;

EID: 84952987879     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1516-y     Document Type: Review

References (135)

1. Aho L, Pikkarainen M, Hiltunen M, Leinonen V, Alafuzoff I (2010) Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis 20:1015–1028. doi:10.3233/JAD-2010-091681
2. Ashe KH, Zahs KR (2010) Probing the biology of Alzheimer’s disease in mice. Neuron 66:631–645. doi:10.1016/j.neuron.2010.04.031
3. Bateman RJ, Munsell LY, Morris JC, Swarm R, Kevin E, Holtzman DM (2006) Quantifying CNS protein production and clearance rates in humans using in vivo stable isotope labeling, immunoprecipitation, and tandem mass spectrometry. Nat Med 12:856–861. doi:10.1038/nm1438.Quantifying
4. Beach TG, Sue LI, Walker DG, Sabbagh MN, Serrano G, Dugger BN et al (2012) Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer’s disease: implications for amyloid imaging. J Alzheimers Dis 28:869–876. doi:10.3233/JAD-2011-111340
5. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15:349–357. doi:10.1038/nn.3028
6. Bertram L, Tanzi RE (2012) The genetics of Alzheimer’s disease. Prog Mol Biol Transl Sci 107:79–100. doi:10.1016/B978-0-12-385883-2.00008-4
7. Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M et al (2007) Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP × Tau transgenic mice. Am J Pathol 171:2012–2020. doi:10.2353/ajpath.2007.070403
8. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
9. Braak H, Braak E, Silverman W, Wisniewski HM, Bobinski M, Wegiel J (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351–357
10. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121:171–181. doi:10.1007/s00401-010-0789-4
11. Braak H, Del Tredici K (2013) Amyloid-β may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer’s disease: a hypothesis. Acta Neuropathol 126:303–306. doi:10.1007/s00401-013-1153-2
12. Braak H, Del Tredici K (2015) The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain 138:2814–2833. doi:10.1093/brain/awv236
13. Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T et al (2015) Human secreted tau increases amyloid-beta production. Neurobiol Aging 36:693–709. doi:10.1016/j.neurobiolaging.2014.09.007
14. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C et al (1998) Neuron loss in APP transgenic mice. Nature 395:755–756. doi:10.1038/27351
15. Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO (2013) Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol 39:593–611. doi:10.1111/nan.12042
16. Do Carmo S, Cuello AC (2013) Modeling Alzheimer’s disease in transgenic rats. Mol Neurodegener 8:37. doi:10.1186/1750-1326-8-37
17. van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2015) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. doi:10.1038/gim.2015.117
18. Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M et al (2012) The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J 31:2261–2274. doi:10.1038/emboj.2012.79
19. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N et al (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282:23818–23828. doi:10.1074/jbc.M701078200
20. Chin J (2011) Selecting a mouse model of Alzheimer’s disease. Methods Mol Biol 670:169–189. doi:10.1007/978-1-60761-744-0_13
21. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333–366. doi:10.1146/annurev.biochem.75.101304.123901
22. Cirrito JR, May PC, O’Dell M, Taylor JW, Parsadanian M, Cramer JW et al (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23:8844–8853. doi:10.1186/1750-1326-8-13
23. Cole G, Neal JW, Singhrao SK, Jasani B, Newman GR (1993) The distribution of amyloid plaques in the cerebellum and brain stem in Down’s syndrome and Alzheimer’s disease: a light microscopical analysis. Acta Neuropathol 85:542–552. doi:10.1007/BF00230495
24. Cox B, Ness F, Tuite M (2003) Analysis of the generation and segregation of propagons: entities that propagate the [PSI+] prion in yeast. Genetics 165:23–33
25. Crimins JL, Rocher AB, Luebke JI (2012) Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. Acta Neuropathol 124:777–795. doi:10.1007/s00401-012-1038-9
26. Cummings BJ, Satou T, Head E, Milgram NW, Cole GM, Savage MJ et al (1996) Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Neurobiol Aging 17:653–659
27. Delaère P, Duyckaerts C, He Y, Pierre F, Hauw JJ (1991) Subtypes and differential laminar distributions of βA4 deposits in Alzheimer’s disease: relationship with the intellectual status of 26 cases. Acta Neuropathol 81:328–335
28. Delaère P, Duyckaerts C, Masters C, Beyreuther K, Piette F, Hauw JJ (1990) Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci Lett 116:87–93
29. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P et al (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13:179–189
30. Duyckaerts C, Colle M-A, Seilhean D, Hauw J-J (1998) Laminar spongiosis of the dentate gyrus: a sign of disconnection, present in cases of severe Alzheimer’s disease. Acta Neuropathol 95:413–420. doi:10.1007/s004010050818
31. Duyckaerts C, Delatour B, Potier M-C (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118:5–36. doi:10.1007/s00401-009-0532-1
32. Duyckaerts C, Hauw J-J (1997) Prevalence, incidence and duration of Braak’s stages in the general population: can we know? Neurobiol Aging 18:362–369
33. Duyckaerts C, Uchihara T, Seilhean D, He Y, Hauw JJ (1997) Dissociation of Alzheimer type pathology in a disconnected piece of cortex. Acta Neuropathol 93:501–507
34. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan Z-XX et al (2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci USA 106:12926–12931. doi:10.1073/pnas.0903200106
35. Eisele YS, Fritschi SK, Hamaguchi T, Obermüller U, Füger P, Skodras A et al (2014) Multiple factors contribute to the peripheral induction of cerebral β-amyloidosis. J Neurosci 34:10264–10273. doi:10.1523/JNEUROSCI.1608-14.2014
36. Eisele YS, Monteiro C, Fearns C, Encalada SE, Wiseman RL, Powers ET et al (2015) Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov. doi:10.1038/nrd4593
37. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H et al (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330:980–982. doi:10.1126/science.1194516
38. Epelbaum S, Youssef I, Lacor P, Chaurand P, Duplus E, Brugg B et al (2015) Acute amnestic encephalopathy in amyloid-ß oligomers injected mice is due to their widespread diffusion in vivo. Neurobiol Aging 36:2043–2052. doi:10.1016/j.neurobiolaging.2015.03.005
39. Fritschi SK, Cintron A, Ye L, Mahler J, Buhler A, Baumann F et al (2014) Abeta seeds resist inactivation by formaldehyde. Acta Neuropathol 128:477–484. doi:10.1007/s00401-014-1339-2
40. Fritschi SK, Langer F, Kaeser SA, Maia LF, Portelius E, Pinotsi D et al (2014) Highly potent soluble amyloid-beta seeds in human Alzheimer brain but not cerebrospinal fluid. Brain 137:2909–2915. doi:10.1093/brain/awu255
41. George S, Ronnback A, Gouras GK, Petit GH, Grueninger F, Winblad B et al (2014) Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimer’s disease. Acta Neuropathol Commun 2:17. doi:10.1186/2051-5960-2-17
42. German DC, White CL, Sparkman DR (1987) Alzheimer’s disease: neurofibrillary changes in nuclei that project to the cerebral cortex. Neuroscience 21:305–312
43. Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M (2015) Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 41:24–46. doi:10.1111/nan.12213
44. Gotz J, Chen F, van Dorpe J, Nitsch RM, Götz J, Chen F et al (2001) Formation of neurofibrillary tangles in P301 l tau transgenic mice induced by Abeta 42 fibrils. Science (80-) 293:1491–1495. doi: 10.1126/science.1062097
45. Gouras GK, Willén K, Tampellini D (2012) Critical role of intraneuronal Aβ in Alzheimer’s disease: technical challenges in studying intracellular Aβ. Life Sci 91:1153–1158. doi:10.1016/j.lfs.2012.06.004
46. Grinberg LT, Rüb U, Ferretti REL, Nitrini R, Farfel JM, Polichiso L et al (2009) The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset? Neuropathol Appl Neurobiol 35:406–416. doi:10.1111/j.1365-2990.2009.00997.x
47. Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2:a006270. doi:10.1101/cshperspect.a006270
48. Hamaguchi T, Eisele YS, Varvel NH, Lamb BT, Walker LC, Jucker M (2012) The presence of Abeta seeds, and not age per se, is critical to the initiation of Abeta deposition in the brain. Acta Neuropathol 123:31–37. doi:10.1007/s00401-011-0912-1
49. Hardy JA, Higgins GA (1992) Alzheimer’ s Disease: The Amyloid Cascade Hypothesis. Science (80-) 256:184–185
50. Harper JD, Lansbury PT Jr (1997) Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66:385–407. doi:10.1146/annurev.biochem.66.1.385
51. Heilbronner G, Eisele YS, Langer F, Kaeser SA, Novotny R, Nagarathinam A et al (2013) Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice. EMBO Rep 14:1017–1022. doi:10.1038/embor.2013.137
52. Héraud C, Goufak D, Ando K, Leroy K, Suain V, Yilmaz Z et al (2013) Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice. Neurobiol Dis 62:100–112. doi:10.1016/j.nbd.2013.09.010
53. Herzig MC, Van Nostrand WE, Jucker M (2006) Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 16:40–54
54. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD et al (2004) Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7:954–960. doi:10.1038/nn1302
55. Heuer E, Rosen RF, Cintron A, Walker LC (2012) Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr Pharm Des 18:1159–1169
56. Hooli BV, Mohapatra G, Mattheisen M, Parrado AR, Roehr JT, Shen Y et al (2012) Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 78:1250–1257. doi:10.1212/WNL.0b013e3182515972
57. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S et al (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (80-) 274:99–102
58. Hyman BT, Van Hoesen GW, Beyreuther K, Masters CL (1989) A4 amyloid protein immunoreactivity is present in Alzheimer’s disease neurofibrillary tangles. Neurosci Lett 101:352–355
59. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science (80-) 225:1168–70
60. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13. doi:10.1016/j.jalz.2011.10.007
61. Irwin DJ, Abrams JY, Schonberger LB, Leschek W, Mills JL, Lee VM et al (2013) Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 70:462–468. doi:10.1001/jamaneurol.2013.1933.Evaluation
62. Jack CR, Jorge J, Vladimir RB (2013) Cerebral amyloid PET imaging in Alzheimer’ s disease. Acta Neuropathol 126:643–657. doi: 10.1007/s00401-013-1185-7
63. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR et al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313:1924–1938. doi:10.1001/jama.2015.4668
64. Jarrett JT, Berger EP, Lansbury PT (1993) The carboxy terminus of the beta-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32:4693–4697. doi:10.1021/bi00069a001
65. Jarrett JT, Lansbury PT (1993) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73:1055–1058. doi:10.1016/0092-8674(93)90635-4
66. Jaunmuktane Z, Mead S, Ellis M, Wadsworth JDF, Nicoll AJ, Kenny J et al (2015) Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 525:247–250. doi:10.1038/nature15369
67. Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70:532–540. doi:10.1002/ana.22615
68. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD et al (2000) Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein transgenic mice. J Neurosci 20:3606–3611
69. Kanmert D, Cantlon A, Muratore CR, Jin M, O’Malley TT, Lee G et al (2015) C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death. J Neurosci 35:10851–10865. doi:10.1523/JNEUROSCI.0387-15.2015
70. Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E et al (2003) Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 24:365–378
71. Kovacs GG (2015) Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 41:3–23. doi:10.1111/nan.12208
72. Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML et al (2014) Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci USA 111:510–514. doi:10.1073/pnas.1318807111
73. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH et al (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077–4081
74. De Lacoste MC, White CL (1993) The role of connectivity in Alzheimer’s disease pathogenesis. A review and model system. Neurobiol Aging 14:1–16
75. Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB et al (1997) Altered metabolism of familial Alzheimer’s disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet 6:1535–1541
76. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M (2011) Soluble Abeta seeds are potent inducers of cerebral beta-amyloid deposition. J Neurosci 31:14488–14495. doi:10.1523/JNEUROSCI.3088-11.2011
77. Le TV, Crook R, Hardy J, Dickson DW (2001) Cotton wool plaques in non-familial late-onset Alzheimer disease. J Neuropathol Exp Neurol 60:1051–1061
78. Lévesque M, Parent A (2005) The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc Natl Acad Sci USA 102:11888–11893. doi:10.1073/pnas.0502710102
79. Lewis J, Dickson DW (2016) Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. doi:10.1007/s00401-015-1507-z
80. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91:12243–12247
81. Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M et al (2013) Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 5:194re2. doi:10.1126/scitranslmed.3006446
82. Mann DMA, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome. J Neurol Sci 89:169–179
83. Mann DMA, Hardy J (2013) Amyloid or tau: the chicken or the egg? Acta Neuropathol 126:609–613. doi:10.1007/s00401-013-1162-1
84. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C et al (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191–199. doi:10.1016/j.neuron.2005.06.030
85. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866
86. Metsaars W, Hauw J-J, Welsem M, Duyckaerts C (2003) A grading system of Alzheimer disease lesions in neocortical areas. Neurobiol Aging 24:563–572
87. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E et al (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781–1784. doi:10.1126/science.1131864
88. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A et al (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature 451:720–724. doi:10.1038/nature06616
89. Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M et al (2003) Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 6:370–377. doi:10.1038/nn1022
90. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G et al (2000) High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050–4058
91. Murakami T, Ishiguro N, Higuchi K (2014) Transmission of systemic AA amyloidosis in animals. Vet Pathol 51:363–371. doi:10.1177/0300985813511128
92. Musiek ES, Holtzman DM (2015) Three dimensions of the amyloid hypothesis: time, space and “wingmen”. Nat Neurosci 18:800–806. doi:10.1038/nn.4018
93. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321–332. doi:10.1016/j.neuron.2004.07.003
94. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421
95. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN et al (2015) Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313:1939–1949. doi:10.1001/jama.2015.4669
96. Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S et al (2015) Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 78:439–453. doi:10.1002/ana.24454
97. Perez SE, Raghanti MA, Hof PR, Kramer L, Ikonomovic MD, Lacor PN et al (2013) Alzheimer’s disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla). J Comp Neurol 521:4318–4338. doi:10.1002/cne.23428
98. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R (2005) Self-propagating, molecular-level polymorphism in Alzheimer’s beta-amyloid fibrils. Science (80-) 307:262–265. doi: 10.1126/science.1105850
99. Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP (2013) Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14:389–394. doi:10.1038/embor.2013.15
100. Pooler AM, Polydoro M, Maury EA, Nicholls SB, Reddy SM, Wegmann S et al (2015) Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’ s disease. Acta Neuropathol Commun 3:1–11. doi:10.1186/s40478-015-0199-x
101. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science (80-) 216:136–144
102. Radde R, Duma C, Goedert M, Jucker M (2008) The value of incomplete mouse models of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35(Suppl 1):S70–S74
103. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T et al (2007) Reducing endogenous Tau ameliorates amyloid beta–Induced deficits in an Alzheimer’s disease mouse model. Science (80-) 316:750–754
104. Ronnback A, Sagelius H, Bergstedt KD, Naslund J, Westermark GT, Winblad B et al (2012) Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiol Aging 33:831.e11–831.e19. doi: 10.1016/j.neurobiolaging.2011.07.012
105. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A et al (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38:24–26
106. Rupp NJ, Wegenast-Braun BM, Radde R, Calhoun ME, Jucker M (2011) Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol Aging 32:2324.e1–2324.e6. doi: 10.1016/j.neurobiolaging.2010.08.014
107. Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S et al (2014) Single APP knock-in mouse models of Alzheimer’s disease. Nat Neurosci 17:661–663. doi:10.1038/nn.3697
108. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N et al (2011) Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci 14:1023–1032. doi:10.1038/nn.2858
109. Schmidt ML, Lee VM, Trojanowski JQ (1991) Comparative epitope analysis of neuronal cytoskeletal proteins in Alzheimer’s disease senile plaque, neurites and neuropil threads. Lab Invest 64:352–357
110. Schneider K, Fangerau H, Michaelsen B, Raab WH-M (2008) The early history of the transmissible spongiform encephalopathies exemplified by scrapie. Brain Res Bull 77:343–355. doi:10.1016/j.brainresbull.2008.09.012
111. Schwab C, Steele JC, Akiyama H, McGeer EG, McGeer PL (1995) Relationship of amyloid β/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism-dementia. Acta Neuropathol 90:287–298. doi:10.1007/BF00296513
112. Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC (1987) Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer’s disease. Science (80-) 235:873–877
113. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJM et al (2014) Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21:221–224. doi:10.3109/13506129.2014.964858
114. Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4:49–60. doi:10.1038/nrn1007
115. St George-Hyslop PH (2000) Molecular genetics of Alzheimer’s disease. Biol Psychiatry 47:183–199
116. Stohr J, Condello C, Watts JC, Bloch L, Oehler A, Nick M et al (2014) Distinct synthetic Abeta prion strains producing different amyloid deposits in bigenic mice. Proc Natl Acad Sci USA 111:10329–10334. doi:10.1073/pnas.1408968111
117. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S et al (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94:13287–13292
118. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S et al (2009) Gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29:13042–13052. doi:10.1523/JNEUROSCI.2362-09.2009
119. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD (2003) Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 62:1287–1301
120. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800
121. Thal DR, Walter J, Saido TC, Fändrich M (2015) Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease. Acta Neuropathol 129:167–182. doi:10.1007/s00401-014-1375-y
122. Vassar R, Kuhn P-H, Haass C, Kennedy ME, Rajendran L, Wong PC et al (2014) Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem 130:4–28. doi:10.1111/jnc.12715
123. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TLS et al (2011) Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C] Pittsburgh compound B data. Ann Neurol 70:857–861. doi:10.1002/ana.22608
124. Walker LC, Bian F, Callahan MJ, Lipinski WJ, Durham RA, LeVine H (2002) Modeling Alzheimer’s disease and other proteopathies in vivo: is seeding the key? Amino Acids 23:87–93. doi:10.1007/s00726-001-0113-7
125. Walker LC, Callahan MJ, Bian F, Durham RZ, Roher AE, Lipinski WJ (2002) Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides 23:1241–1247
126. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A et al (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945–25952
127. Walsh DM, Selkoe DJ (2007) A beta oligomers: a decade of discovery. J Neurochem 101:1172–1184
128. Watts JC, Condello C, Stohr J, Oehler A, Lee J, DeArmond SJ et al (2014) Serial propagation of distinct strains of Abeta prions from Alzheimer’s disease patients. Proc Natl Acad Sci USA 111:10323–10328. doi:10.1073/pnas.1408900111
129. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH et al (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer’s disease. J Neurosci 22:1858–1867
130. Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S et al (2015) η-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526:443–447. doi:10.1038/nature14864
131. Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VLJ et al (2015) A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 16:564–574. doi:10.1038/nrn3983
132. Xiao Y, Ma B, McElheny D, Parthasarathy S, Long F, Hoshi M et al (2015) Aβ(1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. Nat Struct Mol Biol 22:499–505. doi:10.1038/nsmb.2991
133. Ye L, Fritschi SK, Schelle J, Obermüller U, Degenhardt K, Kaeser SA et al (2015) Persistence of Aβ seeds in APP null mouse brain. Nat Neurosci 18:1559–1561. doi:10.1038/nn.4117
134. Ye L, Hamaguchi T, Fritschi SK, Eisele YS, Obermuller U, Jucker M et al (2015) Progression of seed-induced abeta deposition within the limbic connectome. Brain Pathol 25:743–752. doi:10.1111/bpa.12252
135. Yetman MJ, Lillehaug S, Bjaalie JG, Leergaard TB, Jankowsky JL (2015) Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex. Brain Struct Funct. doi:10.1007/s00429-015-1040-9